SCHEMBL23780460

SCHEMBL23780460

Cc1nc(-c2ccc(CNc3cc(C#N)ncn3)cc2)no1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 6/20 0.42
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
HDAC1 Q13547 5/20 0.41
HDAC8 Q9BY41 4/20 0.41
MPO P05164 1/20 0.41
CLK4 Q9HAZ1 4/20 0.39
CYP1A2 P05177 3/20 0.39
TSHR P16473 2/20 0.39
MAPK1 P28482 2/20 0.39
CYP2C19 P33261 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 2/20 0.39
DYRK1A Q13627 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23291888 0.87 ACACB (0.45) HDAC6HDAC1HDAC8CLK4CYP1A2
SCHEMBL23292040 0.86 HDAC8 (0.46) HDAC6HDAC1HDAC8CLK4CYP1A2
SCHEMBL23291999 0.85 MPO (0.44) HDAC6HDAC1HDAC8MPOCLK4
SCHEMBL30172415 0.83 HDAC6 (0.45) HDAC6CTSLCTSBCTSSCTSK
SCHEMBL23780444 0.83 HDAC6 (0.45) HDAC6CTSLCTSBCTSSCTSK
SCHEMBL23780463 0.83 CLK4 (0.52) HDAC6CTSLCTSBCTSSCTSK
SCHEMBL23780453 0.83 PTGS2 (0.44) HDAC6HDAC1HDAC8MPOCLK4
SCHEMBL23780472 0.82 MPO (0.42) HDAC6HDAC1HDAC8MPOCLK4
SCHEMBL23780407 0.81 HDAC6 (0.50) HDAC6CTSLCTSBCTSSCTSK
SCHEMBL23780445 0.80 HDAC6 (0.50) HDAC6HDAC1HDAC8HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US claimed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP claimed
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187712-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 HDAC6 233/4885CTSL 2734/4885CTSB 3757/4885
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 HDAC6 233/4885CTSL 2734/4885CTSB 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.